Hospital Injectable Products · LP-204
Tranexamic acid Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-204Hospital Injectable Products
- Generic identity
- Tranexamic acidInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-204
- Generic ingredient
- Tranexamic acid
- Dosage form
- Injection
- Proposed strength
- 100 mg/mL
- Proposed pack
- Ampoule 5 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
About Tranexamic acid
Tranexamic acid injection is an antifibrinolytic medicine used in defined professional bleeding-management settings. It reduces fibrin breakdown and has a different role from medicines that replace clotting factors or stimulate uterine contraction. Identifying the source of bleeding and the appropriate clinical pathway remains essential. The injectable presentation is distinct from oral tablets and cannot inherit their instructions.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Use occurs within indication-specific protocols that may differ by country and care setting. Clinical assessment includes the cause and severity of bleeding, renal function, thrombosis risk and concurrent treatment. The product must be clearly distinguished from other ampoules used in procedural care. This educational entry contains no trauma, obstetric or surgical regimen, and does not establish candidate-specific approval for any particular bleeding indication.
Important safety considerations
Intrathecal or epidural administration errors with tranexamic acid can be fatal; the injection must be kept distinct from medicines intended for those routes. Other important risks include thrombosis in relevant patients, seizures, hypersensitivity and hypotension associated with inappropriate administration. Renal impairment can affect exposure. New neurological symptoms, severe allergic features, chest pain or suspected thrombosis requires immediate assessment. High-alert identification and route checks are critical.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source specifies a 100 mg/mL ampoule. Confirm exact formulation, total ampoule content and authorized route. Packaging and clinical storage should support clear distinction from local anaesthetic ampoules. No alternative injection route is inferred.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the bleeding indication, renal function, seizure and thrombotic risks, interacting medicines and monitoring. Independently verify ampoule identity and route before preparation or administration.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Tranexamic acid
- Dosage form / presentation
- Injection
- Catalogue strength
- 100 mg/mL
- Catalogue pack
- Ampoule 5 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- Product-specific authorised route, preparation, compatibility and administration instructions are not established by the catalogue record.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- DailyMed: tranexamic acid injection — external reference labelgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-204, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-204.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.